Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Poxel S.A.. (1/28/16). "Press Release: Poxel Provides YE15 Cash and Turnover Figures". Lyon.

Organisations Organisation Poxel S.A. (Euronext: POXEL)
  Organisation 2 NewCap. – Investor Relations & Financial Communications
Products Product imeglimin
  Product 2 PXL770 (Poxel)
Persons Person May, Stephanie (Trophic Communications 201801 before MacDougall European Office)
  Person 2 Alba, Florent (NewCap 201502)
     


POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced its cash position and its turnover for the fiscal year 2015.

As of December 31st, 2015, the cash and cash equivalents amounted to €42.4 million* compared to €10.3 million on December 31st, 2014.

As expected, Poxel did not generate significant revenues in 2015.

These figures are consistent with the Company’s expectations and its growth strategy, which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.


*unaudited


Next financial press release: Year Full-Year Financial Statement, March 31st, 2016


About Poxel SA

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)


Contacts

Investor relations / Media - EU/US
MacDougall Biomedical Communications
Stephanie May or Gretchen Schweitzer
smay@macbiocom.com
+49 89 2424 3494 or + 49 172 861 8540

Investor relations / Media - France
NewCap
Florent Alba/Nicolas Merigeau
poxel@newcap.fr
+33 1 44 71 98 55

   
Record changed: 2016-03-14

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Poxel S.A. (Euronext: POXEL)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top